Document:

Separation Agreement with Christine Pellizzari

 Exhibit 10.21 
 November 29, 2011 
 Via Electronic Mail Delivery—Personal and Confidential

 Ms. Christine Pellizzari 

P.O. Box 505 
 Brookside, New Jersey 07926

 Dear Christine: 
 As
discussed, your employment with Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) shall terminate effective December 31, 2011. This letter (the “Agreement”) summarizes the terms of your separation from
employment and establishes an amicable arrangement under which you release the Company from any and all claims, and, in return, you receive severance pay and other benefits. 
 1. Employment Status; Final Payments; Benefits Cessation: 
 (a)
Final Wage Payments: As noted above, your employment from the Company shall terminate effective December 31, 2011 (the “Separation Date”). Between now and the Separation Date, you agree to continue to perform your duties in a
professional manner. As of the Separation Date, your salary shall cease and you no longer will be entitled to the payment of base salary, bonus, or any form of compensation, except as set forth in this Agreement. On the Separation Date, the Company
shall pay to you (i) all earned but unpaid base salary up to and through the Separation Date, and (ii) all accrued but unused PTO up to and through the Separation Date. 

(b) Final Bonus Payments: You remain eligible for a 2011 bonus; the Company’s assessment of your bonus eligibility shall be
conducted in a manner that is consistent with the Company’s assessment of current employees’ 2011 bonus eligibility. Should you be awarded such a bonus, the Company will pay such bonus to you when it pays 2011 bonuses, if any, to current
employees. Any such bonus will be paid prior to March 15, 2012. 
 (c) Expense Reimbursement: The Company will
reimburse you for all appropriately documented business expenses in accordance with Company policy, provided that you submit all documentation of any such expenses on or before the Separation Date. 

(d) Benefits Cessation: As of the Separation Date, any entitlement you have or might have under a Company-provided benefit plan,
program or practice shall terminate, except as required by law or as otherwise described below. To the extent applicable, you shall receive benefit continuation information under separate cover. 

(e) Stock Option Grants: As set forth in the Company’s 2006 Stock Option and Grant Plan, as amended, and associated equity
award agreements between you and the Company (collectively, the “Equity Award Documents”), your option to purchase the Company’s common stock shall cease vesting on the Separation Date, except as otherwise provided in this Agreement.
All of your rights and obligations to stock options, including without limitation, vesting, exercise and expiration, are governed by the terms and conditions of the Equity Award Documents, except as otherwise described below. In accordance with the
Equity Award Documents, to the extent that you have vested but unexercised stock option grants, you will have ninety days after the Separation Date to exercise the vested portion of said options. Except as otherwise provided in this Agreement, stock
options which remain unvested as of the Separation Date will be forfeited. 
 (f) Notice of Termination: This letter
agreement shall serve as the notice of termination contemplated by Section 3(f) of the Employment Agreement. Pursuant to Section 3(d) of the Employment Agreement, your employment is being terminated without “Cause.” 

 2. Consideration: In exchange for, and in consideration of, your execution of and compliance
with this Agreement, including the Certificate (which is described in Section 4(g) below and attached hereto as Exhibit B), and any other agreement with Aegerion that survives the termination of your employment, the Company will provide
you with the following: 
 (a) Severance Payments: Aegerion will pay to you your current weekly base
salary of $5,001.00 for the period of 52 weeks (the “Severance Period”), for a total gross severance payment of $260,052.00. These payments, which will be made on the Company’s regularly scheduled payroll dates for all employees, are
referred to herein as the “Severance Payments.” The Severance Payments shall commence on the first Company payroll date which is on or after the 8th day following the date on which the Company receives a copy of the Certificate executed by you. Each Severance Payment
shall be treated as a separate payment for purposes of Section 409A of the Internal Revenue Code, as amended. Notwithstanding the foregoing, the Severance Payments set forth in this Section shall be reduced dollar for dollar by any compensation
you receive from another employer during the Severance Period if you become re-employed during such time. You agree to give prompt notice of any employment you obtain during the Severance Period and shall respond promptly to any reasonable inquiries
regarding your professional activities. You agree that if the Company makes any overpayments of Severance Payments, you will promptly return any such overpayments to the Company and/or hereby authorize deductions of such overpayments from future
Severance Payment amounts. 
 (b) COBRA Premium Payments: Subject to the terms and conditions provided for in the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), and provided you have timely and properly elected COBRA coverage in accordance with the Company’s COBRA election procedures, the Company shall continue to
pay its share of your group medical and dental insurance premiums during the Severance Period or until such earlier time as you (i) obtain alternate medical insurance or (ii) become ineligible for COBRA benefits. You remain responsible for
your share of such premiums during the Severance Period. You agree promptly to notify the Company if and when you become eligible for alternate medical coverage during the Severance Period. Following the Severance Period, you shall be responsible
for 100% of the COBRA premium should you elect to maintain this coverage. 
 (c) Acceleration of Stock
Options: On the Separation Date, the Company estimates that 101,777 of the stock options granted to you under the Equity Award Documents will be unvested. In consideration of your execution of this Agreement and the attached Certificate, on or
after the 8th day following the date on which the Company
receives a copy of the Certificate executed by you, the Company will accelerate the vesting of 50% (or 50,888) of the unvested stock options such that these options will be deemed to have been fully vested and exercisable as of the Separation Date.
In accordance with the Equity Award Documents, you will have ninety days from the Separation Date to exercise each stock option. 
 (d) Outplacement Services: To assist you with your career transition, Aegerion will provide you with six weeks of outplacement services through its preferred vendor, Keystone Associates, up to a
maximum cost of $3,000. 
 (e) Acknowledgement of Consideration to Support Agreement: You expressly acknowledge and agree
that the payments and benefits provided to you under this Section 2 are a benefit to which you are not otherwise entitled to receive and are being given to you solely in exchange for your promise to be bound by the terms of this Agreement and
the Certificate. 
 3. Taxes: All payments set forth in this Agreement shall be subject to all applicable federal, state and/or
local withholding and/or payroll taxes, and the Company may withhold from any amounts payable to you (including any amounts payable pursuant to this Agreement) in order to comply with such withholding obligations. 

4. General Release of Claims; ADEA Waiver; Accord and Satisfaction; Exhibit B: 

(a) General Release: In exchange for the amounts described in Section 2, and other good and valuable consideration, the
receipt of which you hereby acknowledge, you and your representatives, agents, estate, heirs, 

 
successors and assigns (“You”), absolutely and unconditionally hereby release, remise, discharge, indemnify and hold harmless the Released Parties (defined in Section 4(f) below),
from any and all actions or causes of action, suits, claims, complaints, contracts, liabilities, agreements, promises, torts, debts, damages, controversies, judgments, rights and demands, whether existing or contingent, known or unknown, suspected
or unsuspected, arising on or before the Effective Date of this Agreement (the “Claims”). 
 This general release
includes, without limitation, any and all Claims arising out of or in connection with: 
 (i) your employment,
change in employment status, and/or termination of employment with the Company; 
 (ii) any federal, state or
local law, constitution or regulation regarding either employment, employment benefits, or employment discrimination and/or retaliation including, without limitation, the National Labor Relations Act, as amended; Title VII of the Civil Rights Act of
1964, as amended, 42 U.S.C. 2000e et seq.; Sections 1981 through 1988 of Title 42 of the United States Code, as amended; the Employee Retirement Income Security Act of 1974, as amended, 29 U.S.C. 1001 et seq.; the Workers
Adjustment and Retraining Notification Act, 29 U.S.C. Section 2101 et seq.; the Immigration Reform and Control Act, as amended; the Americans with Disabilities Act of 1990, as amended; the Fair Labor Standards Act, as amended; the
Occupational Safety and Health Act, as amended; the Family and Medical Leave Act of 1993 (“FMLA”), as amended; the Consolidated Omnibus Budget Reconciliation Act, as amended; and laws relating to workers compensation, family and medical
leave, discrimination on the basis of race, color, religion, creed, sex, sex harassment, sexual orientation, marital status, pregnancy, national origin, ancestry, handicap, disability, veteran’s status, alienage, blindness, present or past
history of mental disorders or physical disability, candidacy for or activity in a general assembly or other public office, constitutionally protected acts of speech, whistleblower status, use of tobacco products outside course of employment,
membership in any organization engaged in civil defense, veteran’s status, any military service, application for military service, or any other federal, state or local civil or human rights law or any other local, state or federal law,
regulation or ordinance; 
 (iii) any New Jersey state or local laws respecting employment, including but not
limited to, the New Jersey Family Leave Act, the New Jersey Law Against Discrimination, the New Jersey Wage and Hour Law, the New Jersey Home Work Law and the New Jersey Industrial Home Work Law, New Jersey Workers’ Compensation Law, the New
Jersey Equal Pay Act, the New Jersey Occupational Safety and Health Law, the New Jersey Conscientious Employee Protection Act, the New Jersey Temporary Disability Benefits Law, the New Jersey Family Insurance Law, all as amended, and New Jersey laws
regulating disability benefits; 
 (iv) breach of contract (express or implied) or breach of the implied
covenant of good faith and fair dealing; 
 (v) wrongful termination, intentional or negligent infliction of
emotional distress, negligent misrepresentation, intentional misrepresentation, fraud, defamation, promissory estoppel, false light invasion of privacy, conspiracy, violation of public policy; and 

(vi) any other tort, statutory or common law cause of action. This release is intended by You to be all encompassing and
a full and total release of any Claims, whether specifically enumerated herein or not, that You may have or have had against the Released Parties up to the date you execute this Agreement. You further agree to release and discharge the Released
Parties from any and all claims which might be made by any other person or organization on your behalf and you specifically waive any right to become, and promise not to become, a member of any class in a case in which a claim or claims against the
Company are made involving any matters subject to release pursuant to this Section 4(a). 
 (b) Waiver of Rights and
Claims Under the Age Discrimination in Employment Act of 1967: Because you are 40 years of age or older, you hereby are informed that you have or might have specific rights and/or claims 

 
under the Age Discrimination and Employment Act of 1967, as amended (the “ADEA”), and you agree and understand that: 

(i) In consideration for the amounts described in Section 2, which you are not otherwise entitled to receive, you
specifically waive such rights and/or claims under the ADEA to the extent that such rights and/or claims arose prior to or on the date this Agreement was executed; 

(ii) You understand that rights or claims under the ADEA which may arise after the date this Agreement is executed are
not waived by you; 
 (iii) You acknowledge that you have been advised that you should consult with your counsel
of choice prior to executing this Agreement, that you have forty-five (45) days to review this Agreement and consider its terms before signing it, and that the review period will not be affected or extended by any revisions, whether material or
immaterial, that might be made to this Agreement, and you have not been subject to any undue or improper influence interfering with the exercise of your free will in deciding whether to consult with counsel; 

(iv) You are hereby informed of: (1) the group of individuals considered for inclusion in the reduction in force,
(2) the selection criteria used to determine the individuals within the group who are included in the reduction in force, (3) the job title and ages of all individuals within the group who have been selected for inclusion in the reduction
in force, and (4) the job title and ages of all individuals within the group who have not been selected for inclusion in the reduction in force. A copy of the lists and information referenced in this paragraph are attached hereto as Exhibit
A; 
 (v) You have carefully read and fully understand all of the provisions of this Agreement, you
knowingly and voluntarily agree to all of the terms set forth in this Agreement, and you acknowledge that in entering into this Agreement, you are not relying on any representation, promise or inducement made by the Company or its representatives
with the exception of those promises contained in this document; and 
 (vi) You may revoke this Agreement for a
period of seven (7) days following your execution hereof and all rights and obligations of both parties under this Agreement shall not become effective or enforceable until the seven (7) day revocation period has expired. Please see
Section 10 for more details. 
 (c) Interpretation: The foregoing release-of-claims provisions set forth in Sections
4(a) and 4(b) shall be given the broadest possible interpretation permitted by law. The enumeration of specific claims therein shall not be interpreted to exclude any other claims not specifically enumerated therein. 

(d) Exclusions from General Release: Excluded from the General Release set forth in Sections 4(a) and 4(b) are any claims or
rights that cannot be waived by law, including your right to file a charge with an administrative agency, including the EEOC, or assist or participate in any agency investigation, hearing or proceeding. You, however, are waiving your right to
recover money in connection with any such agency charge or investigation, hearing or proceeding. You also are waiving your right to recover any money in connection with a charge filed by any other individual or individuals, or by the EEOC or any
other federal or state agency, on your behalf. 
 (e) Accord and Satisfaction: The payments set forth in Sections 1 and 2
shall be complete and unconditional payment, settlement, accord and/or satisfaction with respect to all obligations and liabilities of the Released Parties to You including, without limitation, all claims for back wages, salary, vacation pay, sick
pay, notice pay, bonuses, commissions or other incentive compensation, severance pay, all other forms of compensation or benefits, attorney’s fees, or other costs or sums. 

(f) Definition of Released Parties: As used in this Agreement, “Released Parties” shall mean: (i) Aegerion
Pharmaceuticals, Inc.; (ii) all of Aegerion’s past, present, and future subsidiaries, parents, affiliates and divisions; (iii) all of Aegerion’s successors and/or assigns, as well as legal representatives; and (iv) all of
Aegerion’s past, present, and future officers, directors, managers, employees, shareholders, owners, attorneys, agents, insurers, 

 
employee benefit plans (including such plans’ administrators, trustees, fiduciaries, record-keepers, and insurers), and legal representatives (all both individually, in their capacity acting
on Aegerion’s behalf and in their official capacities). 
 (g) Obligation to Update Release of Claims and Execute
Exhibit B on the Separation Date: You acknowledge and agree that one of the primary purposes of this Agreement is for the Company to pay you certain severance benefits in exchange for your release of all claims against the Released
Parties. Because you will execute this Agreement prior to the Separation Date, as a condition of receiving the severance benefits set forth in Section 2 above, on the Separation Date, you must execute (and not revoke) the certificate, attached
hereto as Exhibit B (the “Certificate”), in which you will extend the release of claims in Sections 4(a) and 4(b) to any and all claims (including ADEA claims) that arose from the date you signed this Agreement through the date you
sign the Certificate. You acknowledge and agree that you will not be eligible for any of the severance benefits set forth in Section 2 unless you execute and do not revoke the Certificate. 

5. Covenant Not to Sue: A “covenant not to sue” is a legal term which means that you promise not to file a lawsuit in court. It
is different from the release of claims contained in Sections 4(a) and 4(b) above. Besides waiving and releasing the claims covered by Sections 4(a) and 4(b), you further agree never to sue the Released Parties in any forum based on the claims, laws
or theories covered by the release language in Sections 4(a) and (b). You represent and warrant that you have not filed any complaints, charges, or claims for relief against the Released Parties with any local, state or federal court or
administrative agency, with the sole exception of your right to pursue a state unemployment claim. Notwithstanding this Covenant Not To Sue, you may bring a claim to enforce the terms of this Agreement, to challenge the validity of the ADEA waiver
described in Section 4(b), or to pursue state unemployment benefits. Except as set forth in Section 4(d) or as permitted pursuant to this Section 5, in the event that you institute any other action, that claim shall be dismissed upon
the presentation of this Agreement and you shall reimburse the Company for all legal fees and expenses incurred in defending such claim and obtaining its dismissal. 
 6. Company Files, Documents and Other Property: By the Separation Date, you agree to return to the Company all Company property and materials, including but not limited to, all hardware,
personal computers, laptops, CDs/DVDs, intangible information stored on CDs/DVDs, software programs and data compiled with the use of those programs, software passwords or codes, tangible copies of trade secrets and confidential information,
cellular phones, PDAs, telephone charge cards, manuals, building keys and passes, names and addresses of all Company customers and potential customers, customer lists, customer contracts, sales information, memoranda, sales brochures, business or
marketing plans, reports, projections, and any and all other information or property previously or currently held or used by you that is or was related to your employment with the Company. You agree that if you discover any other Company or
proprietary materials in your possession after the Separation Date, you will immediately notify the Company and return such materials to the Company. 
 7. No Liability or Wrongdoing: You understand and agree that this Agreement constitutes a final compromise of the claims released thereby, and is not an admission by the Released Parties
that any such claims exist and/or of liability by the Released Parties with respect to such claims. Nothing in this Agreement, nor any of the proceedings connected with it, is to be construed as, offered as, received as, or deemed to be evidence of
an admission by the Released Parties of any liability or unlawful conduct whatsoever, and each of the Released Parties expressly deny any such liability or wrongdoing. 
 8. Future Conduct: 
 (a) Restrictive Covenants: You confirm
the existence and continued validity of your Employee Confidentiality, Assignment, and Noncompetition Agreement (the “Covenants Agreement”) dated October 4, 2010, a copy of which is enclosed herewith. You agree that your obligations
under the Covenants Agreement expressly survive the cessation of your employment. If you fail to abide by your obligations under the Covenants Agreement, the Company immediately may terminate all severance benefits set forth in Section 2 in
addition to, and not in lieu of, seeking all other legal and equitable relief. 

 (b) Non-disparagement: You agree not to take any action or make any statement,
written or oral, which disparages or criticizes the Released Parties, their officers, directors, investors or employees, the Released Parties’ business practices, or which disrupts or impairs their normal operations, including actions that
would (i) harm the Released Parties’ reputation with their current and prospective clients, business partners, or the public; or (ii) interfere with existing contracts or employment relationships with current and prospective clients,
business partners or Released Parties’ employees. 
 (c) Confidentiality of this Agreement: You shall maintain
confidentiality concerning this Agreement, including the substance, terms, existence and/or any discussions relating to this Agreement. Except as required pursuant to legal process, you will not discuss the same with anyone except your immediate
family and accountants or attorneys when such disclosure is necessary for them to render professional services. Nothing herein shall prohibit or bar you from providing truthful testimony in any legal proceeding or in communicating with any
governmental agency or representative or from making any truthful disclosure required, authorized or permitted under law; provided however, that in providing such testimony or making such disclosures or communications, you will use your best efforts
to ensure that this Section is complied with to the maximum extent possible. However, you will be prohibited to the fullest extent authorized by law from obtaining monetary damages in any agency proceeding in which you do so participate. 

(d) Breach; Remedies: In the event that you breach this Agreement and/or the Covenants Agreement, you agree that (i) the
Company shall be relieved of its obligations to make the payment under Section 2, (ii) if such payment already has been made, you agree to repay it to the Company, and (iii) the Company shall be entitled to recover its attorneys’
fees and costs incurred in enforcing its rights under this Agreement, to the extent such recovery is not prohibited by law. This remedy shall be, in addition to, and not as an alternative to, any other remedies at law or in equity available to the
Company. 
 9. Representations and Governing Law: 
 (a) Integration: This Agreement sets forth the complete and sole agreement between the parties and supersedes any and all other agreements or understandings, whether oral or written, express or
implied, except for the Covenants Agreement, the Equity Award Documents, the Employment Agreement (specifically, those sections that survive by their terms and which are not superseded or modified by any terms set forth herein), the Consulting
Agreement (see section 9(f), and the Indemnification Agreement between the Company and you, which remain in full force and effect in accordance with their terms. This Agreement may not be changed or rescinded except upon the express written consent
of both you and an authorized Company officer. Any waiver of any provision of this Agreement shall not constitute a waiver of any other provision of this Agreement unless expressly so indicated otherwise. The language of all parts of this Agreement
shall in all cases be construed as a whole according to its fair meaning and not strictly for or against any of the parties. 

(b) Governing Law and Choice of Venue: Waiver of Jury Trial: This Agreement shall be deemed to be made and entered into in the
Commonwealth of Massachusetts. This Agreement and any claims arising out of this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth
of Massachusetts and shall in all respects be interpreted, enforced and governed under the internal and domestic laws, without giving effect to the principles of conflicts of laws of such Commonwealth. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 (c) Severability: If any provision of this Agreement, or part thereof, is held invalid, void or voidable as against public policy or otherwise, the invalidity shall not affect other provisions, or
parts thereof, which may be given effect without the invalid provision or part. To this extent, the provisions, and parts thereof, of this Agreement are declared to be severable. 

(d) Assignment: You shall not assign this Agreement. The Company may assign this Agreement. The benefits of this Agreement shall
inure to the successors and assigns of the Company and the Released Parties and to your successors. 

 (e) Acknowledgment of Company’s Compliance with Applicable Law: You represent
that you have not been subject to any retaliation or any other form of adverse action by the Released Parties for any action taken by you as an employee or resulting from your exercise of or attempt to exercise any statutory rights recognized under
federal, state or local law. You agree that you have been paid all unpaid wages and accrued unused vacation and/or personal time as of the Separation Date. You also agree that you have received all time off, whether pursuant to the FMLA, state law
or Company policy or benefit program, and that none of your rights have been violated under any of these statutes, policies or programs. 
 (f) Cooperation; Consulting: 
 (i) By signing this
Agreement, you agree to cooperate with the Company and its attorneys at reasonable times and places in the prosecution and/or defense of any legal action wherein the Company is a party and that involves any facts or circumstances arising during the
course of your employment with the Company. Such cooperation includes, but is not limited to, meeting with the Company’s attorneys at reasonable times and places to discuss your knowledge of pertinent facts, appearing as required at deposition,
arbitration, trial or other proceeding to testify as to those facts, and testifying truthfully to the best of your abilities at any such proceeding. The Company shall reimburse you for any reasonable and approved out-of-pocket costs and expenses you
incur in connection with such cooperation. 
 (ii) In addition, you and the Company agree to enter into a
Consulting Agreement pursuant to which you agree to make yourself available to assist the Company, including its new general counsel, regarding any transition-related issues for up to six months. 

10. Review Period; Expiration of this Offer: If you accept the terms and conditions of this letter agreement, please sign it and return it
to me within forty-five (45) days from the date you received it (i.e., January 12,2012). Please note that if you do not return an executed copy of this Agreement on or before January 12, 2012, this offer will expire. As set forth in
Section 4(b)(vi) above, for the period of seven (7) days from the date when this Agreement becomes executed by you, you have the right to revoke this Agreement by written notice to me. For such a revocation to be effective, it must be
delivered so that I receive it before the expiration of the seven (7) day revocation period. This Agreement shall become effective on the first day following the expiration of the revocation period, i.e., the eighth day following your
execution of it (the “Effective Date”). Because this Agreement includes a waiver and release of your rights, Aegerion advises you to consult with an attorney prior to executing it. 
 If this letter correctly states the understanding and agreement we have reached please indicate your acceptance by countersigning the enclosed copy and returning it to me by 5:00 p.m. EST on
January 12, 2012. 
  

			
	Very truly yours,
	
	Aegerion Pharmaceuticals, Inc.
		
	By:	 	/s/ Marc D. Beer
	Title:	 	CEO

 PLEASE REVIEW CAREFULLY 

THIS AGREEMENT CONTAINS A RELEASE OF CERTAIN LEGAL RIGHTS WHICH YOU MAY HAVE. YOU SHOULD CONSULT WITH AN ATTORNEY REGARDING SUCH RELEASE AND OTHER
ASPECTS OF THIS AGREEMENT BEFORE SIGNING THIS AGREEMENT. 
 YOUR EMPLOYMENT BY THE COMPANY WILL TERMINATE AS OF DECEMBER 31, 2011. SUCH
TERMINATION WILL NOT BE AFFECTED BY YOUR ACCEPTANCE OR FAILURE TO ACCEPT THIS AGREEMENT. IF YOU DO NOT ACCEPT THIS AGREEMENT, YOU WILL NOT RECEIVE THE PAYMENTS AND BENEFITS SET FORTH IN SECTION 2. 

YOU REPRESENT THAT YOU HAVE READ THE FOREGOING AGREEMENT, FULLY UNDERSTAND THE TERMS AND CONDITIONS OF SUCH AGREEMENT AND ARE VOLUNTARILY EXECUTING
THE SAME. 
 IN ENTERING INTO THIS AGREEMENT, YOU DO NOT RELY ON ANY REPRESENTATION, PROMISE OR INDUCEMENT MADE BY THE RELEASED PARTIES
WITH THE EXCEPTION OF THE CONSIDERATION IN THIS DOCUMENT. 
  

					
	ACCEPTED:	 		 	
			
	/s/ Christine Pellizzari	 		 	Date: November 29, 2011
	Ms. Christine Pellizzari	 		 	

 EXHIBIT A 

 

	1.	The Company recently has made the business decision to close its New Jersey office. As a result of this decision, the Company will conduct a reduction in force at its
New Jersey office. 

  

	2.	The group of individuals considered for the Company’s reduction in force is all individuals employed in the New Jersey office. 

 

	3.	The Company plans to terminate the employment of all but one of the individuals employed at the New Jersey office. Four of the six employees at the New Jersey office
will be separated from employment effective December 31, 2011. The Company expects that one employee will remain employed until February 28, 2012, in order to transition critical functions in which he has specific knowledge.

  

	4.	All persons who are being offered consideration under the attached release agreement must sign the agreement and return it to the Company within 45-days after receiving
it. Once the employee has signed the agreement, he or she has seven days to revoke it. 

  

	5.	Set forth below is a listing of the ages and job titles of all employees within the group noted above who were and were not selected for inclusion in the reduction in
force. 

 EMPLOYEES SELECTED 

 

							
	 JOB TITLE
	  	AGE	 	  	 EXPECTED TERMINATION
DATE

	 Executive Assistant
	  	 	40	  	  	12/31/11
	 Executive Assistant
	  	 	46	  	  	12/31/11
	 Administrative Assistant
	  	 	28	  	  	12/31/11
	 Executive Vice President/ General Counsel
	  	 	44	  	  	12/31/11
	 Chief Accounting Officer
	  	 	53	  	  	2/28/12

 EMPLOYEE NOT SELECTED 

 

			
	 JOB TITLE
	  	 AGE

	 Director of Manufacturing
	  	44

 EXHIBIT B 

CERTIFICATE UPDATING RELEASE OF CLAIMS 
 I, Christine Pellizzari, hereby acknowledge and certify that I entered into a Separation Agreement with Aegerion Pharmaceuticals, Inc. (the “Company”), dated
                     (the “Agreement”). Pursuant to that Agreement, I am required to execute this certificate, which updates the
release of claims set forth in Sections 4(a) and 4(b) of the Agreement (this “Certificate”) in order to receive the severance benefits set forth in Section 2 of the Agreement. I, therefore, agree as follows: 

 

	 	1.	A blank copy of this Certificate was attached to the Agreement as Exhibit B. I hereby certify and acknowledge that I received the Agreement and this Certificate
at least 45 days before I was required to sign them. 

  

	 	2.	In consideration of the severance payments and benefits described in Section 2 of the Agreement, for which I become eligible only if I sign this Certificate, I
hereby extend the release of claims set forth in Sections 4(a) and 4(b) of the Agreement to any and all claims that arose after the date I signed the Agreement through the date I signed this Certificate, subject to all other exclusions and terms set
forth in Sections 4 of the Agreement. 

  

	 	3.	In Section 4(b) of the Agreement, the Company made a number of disclosures to me regarding my rights under the Age Discrimination in Employment Act (the
“ADEA”). I understand that in signing this Certificate in consideration for the amounts described in Section 2 of the Agreement, I am specifically waiving such rights and/or claims under the ADEA to the extent that such rights and/or
claims arose prior to or on the date that the Certificate is executed by me. I also make the following acknowledgements and representations: 

  

	 	i.	I understand that rights or claims under the ADEA which may arise after the date this Certificate is executed are not waived by me; 

 

	 	ii.	I acknowledge that I have been advised that I should consult with my counsel of choice prior to executing this Certificate, that I have had at least forty-five
(45) days to review this Certificate and consider its terms before signing it, and I have not been subject to any undue or improper influence interfering with the exercise of my free will in deciding whether to consult with counsel;

  

	 	iii.	In Section 4(b)(iv) of the Agreement, I was informed of: (1) the group of individuals considered for inclusion in the reduction in force, (2) the
selection criteria used to determine the individuals within the group who are included in the reduction in force, (3) the job title and ages of all individuals within the group who have been selected for inclusion in the reduction in force, and
(4) the job title and ages of all individuals within the group who have not been selected for inclusion in the reduction in force. A copy of the lists and information referenced in this paragraph were attached to the Agreement as Exhibit
A; 

  

	 	iv.	I have carefully read and fully understand all of the provisions of this Certificate, I knowingly and voluntarily agree to all of the terms set forth in this
Certificate, and I acknowledge that in entering into this Certificate, I am not relying on any representation, promise or inducement made by the Company or its representatives with the exception of those promises contained in this Certificate and
the Agreement; and 

  

	 	v.	I understand that I may revoke this Certificate for a period of seven (7) days following my execution hereof. I further understand that this Certificate shall not
become effective or enforceable until the seven (7) day revocation period has expired (i.e., on the eighth day following my execution of it). If I wish to revoke the Certificate, I must provide written notice of my revocation to the
Company as set forth in Section 10 of the Agreement such that the Company receives it prior to the expiration of the revocation period. 

	 	4.	I agree that this Certificate is part of this Agreement. 

  

	
	  
	Christine Pellizzari
	
	  
	DateFirst Amendment to Lease

 Exhibit 10.22 
 FIRST AMENDMENT TO LEASE 
 THIS FIRST AMENDMENT TO LEASE, dated as of
November 7, 2011 (this “Amendment”), between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and AEGERION PHARMACEUTICALS, INC. a Delaware corporation (“Tenant”), for certain
premises located in the building in Riverfront Office Park at 101 Main Street, Cambridge, Massachusetts (“Building”). 

RECITALS: 

A. Landlord and Tenant entered into that certain Gross (BY)-INS Office Lease dated for reference December 22, 2010 (as amended, the
“Lease”), for premises currently consisting of approximately 8,741 rentable square feet (the “Original Premises”) on the 18th floor of the Building, 
 B. Landlord and Tenant desire to amend the Lease to provide for the expansion of the Original Premises. 
 C. All terms, covenants and conditions contained in this Amendment shall have the same meaning as in the Lease, and, shall govern should a conflict exist with previous terms and conditions. 

AGREEMENT: 
 NOW, THEREFORE, in consideration of the foregoing recitals and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as
follows: 
 1. Defined Terms. All terms defined in the Lease retain their meaning herein, unless specified herein to the
contrary. 
 2. Additional Space. Tenant wishes to lease from Landlord, and Landlord wishes to lease to Tenant, in
addition to the Original Premises, for a term co-terminus with the Term of the Lease for the Original Premises, approximately 3,978 rentable square feet on the 18th floor of the Building, as approximately depicted on Exhibit A attached hereto
and made a part hereof (the “Additional Space”). Effective January 1, 2012, the Premises subject to the Lease shall consist of the Original Premises as expanded to include the Additional Space, and all references in the Lease to the
“Premises”, unless otherwise provided for in this Amendment, shall refer to such expanded space, which shall consist of approximately 12,719 rentable square feet. 
 3. Rent Schedule. Until January 1,2012, the Annual Rent and Monthly Installment of Rent for the Original Premises shall remain as per the Lease. Effective January 1,2012, Annual Rent and
Monthly Installments of Rent for the entire Premises as expanded shall be payable as follows: 
  

																			
	 Period
	  	Rentable Square
Footage	 	  	Rent
Per Square Foot	 	  	Annual Rent	 	  	Monthly Installment
of Rent	 
	 from
	 	 to
	  	  	  	  
	 1/1/2012
	 	 12/31/2012
	  	 	12,719	  	  	$	44.00	  	  	$	559,636.00	  	  	$	46,636.33	  
	 1/1/2013
	 	 12/31/2013
	  	 	12,719	  	  	$	48.00	  	  	$	610,512.00	  	  	$	50,876.00	  
	 1/1/2014
	 	 12/31/2014
	  	 	12,719	  	  	$	50.00	  	  	$	635,950.00	  	  	$	52,995.83	  
	 1/1/2015
	 	 12/31/2015
	  	 	12,719	  	  	$	50.00	  	  	$	635,950.00	  	  	$	52,995.83	  

 4. Rent Adjustments and Tenant’s Proportionate Share. Article 4 of the Lease remains in full
force and effect. Effective as of January 1,2012, Tenant’s Proportionate Share shall be 3.8%. 
 5. Condition of
Original Premises and Additional Space. 

 (a) Provided the Lease is in full force and effect and there is then no Event of Default
under any of the terms and conditions of the Lease, Landlord shall pay Tenant the sum of the lesser of (a) the actual cost of the work specified below, or (b) $39,780.00 (the “Allowance”), for the improvements to the Premises
desired by Tenant. The Allowance shall be paid within thirty (30) days after Landlord’s receipt of all of the following: (i) paid invoices for all work done by Tenant in the Premises; (ii) final mechanic lien waivers for all work
done by Tenant in the Premises and other evidence reasonably required by Landlord that the work has been completed, paid for in full and is lien-free; and (iii) if required, a certificate of occupancy for the Premises, All construction plans
and contractors must be approved by Landlord before work can commence, and all of the provisions of the Lease (including, without limitation, Article 6, Alterations, and Article 11, Insurance) shall apply to such construction. If the work is not
completed and the conditions precedent to Landlord’s payment of the Allowance are not satisfied by December 31, 2012, Landlord shall have no further obligation to pay the Allowance; provided, however, that Tenant may elect, by notice to
Landlord given prior to December 31, 2012, to apply the amount of any unused Allowance against Tenant’s rental obligations hereunder. The foregoing shall not affect Tenant’s continuing right to the TI Allowance under the terms of the
original Lease. In addition, Landlord agrees, at its expense to separate the Additional Space form the original Premises (e.g, walls, doors, utilities, HVAC). 
 (b) Except as set forth in the preceding subparagraph, Tenant acknowledges that Landlord shall have no obligation to perform any construction or make any additional improvements or alterations, or to
afford any allowance to Tenant for improvements or alterations, in connection with this Amendment. Tenant accepts the Original Premises and Additional Space in their “as is” condition, and acknowledges that all previous obligations of
Landlord to perform any construction or make any improvements or alterations, and/or to afford any allowance to Tenant for the cost of same have been performed and satisfied in full. 

6. Additional Expansion Right. Provided that there is then no Event of Default under the terms, covenants and conditions of the
Lease, Tenant shall have the right to lease approximately 8,453 rentable square feet on the 18th floor of the Building, as approximately depicted on Exhibit B attached hereto and made a part hereof (the “Second Additional Space”)
for occupancy on or before April 1, 2015 (the “Delivery Date”). In the event that Tenant desires to exercise its option, it shall deliver notice of such exercise to Landlord on or before May 31, 2014, failing which Landlord may
lease the Second Additional Space to any third party on whatever basis Landlord desires, and Tenant shall have no further rights with respect to the Second Additional Space. In the event the prior tenant of the Second Additional Space fails to
vacate the Second Additional Space in a timely manner, the Delivery Date shall be adjusted accordingly. If Tenant exercises this expansion option, effective as of the Delivery Date, the Second Additional Space shall automatically be included within
the Premises and subject to all the terms and conditions of the Lease, except as follows: 
 (a) Tenant’s Proportionate
Share shall be recalculated, using the total square footage of the Premises, as increased by the Second Additional Space. 
 (b)
The Second Additional Space shall be leased on an “as is” basis and Landlord shall have no obligation to improve the Second Additional Space or grant Tenant any improvement allowance thereon. 

(c) The Monthly Installment of Rent for the Second Additional Space from the Delivery Date through December 31, 2015 shall be
$35,220.83 ($50.00 per RSF). 
 (d) If requested by Landlord, Tenant shall, prior to the beginning of the term for the Second
Additional Space, execute a written memorandum confirming the inclusion of the Second Additional Space. 
 (e) If Tenant
exercises this expansion option, and subsequently exercises its extension option under Article 40 of the Lease, said extension option shall be available only with respect to the entire Premises as then constituted, including the Second Additional
Space. 

  
 2 

 7. Brokers. Landlord and Tenant each (i) represents and warrants to the other
that it has not dealt with any broker or finder in connection with this Amendment, other than Richard Barry Joyce & Partners, for Tenant, and Cushman & Wakefield, for Landlord, whose commissions, if any, shall be paid by Landlord
pursuant to separate agreement, and (ii) agrees to defend, indemnify and hold the other harmless from and against any losses, damages, costs or expenses (including reasonable attorneys’ fees) incurred by such other party due to a breach of
the foregoing warranty by the indemnifying party. 
 8. Parking. Effective January 1,2012, the provision for
“Parking” as set forth on the Reference Pages and as amended is deleted and the following provision shall be substituted in its place: “13 passes at $235.00 per space per month (see Article 39).” If Tenant exercises its option
for the Second Additional Space, Article 39 shall be further amended to read “22 passes at $235.00 per space per month.” 
 9. Tenant’s Authority. Each of the persons executing this Amendment on behalf of Tenant represents and warrants that Tenant has been and is qualified to do business in the state in which the
Building is located, that the entity has full right and authority to enter into this Amendment, and that all persons signing on behalf of the entity were authorized to do so by appropriate actions. Tenant agrees to deliver to Landlord,
simultaneously with the delivery of this Lease, a corporate resolution, evidencing the due authorization of Tenant to enter into this Lease. Each of the persons executing this Amendment on behalf of Landlord represents and warrants that Landlord has
been and is qualified to do business in the state in which the Building is located, that Landlord has full right and authority to enter into this Amendment, and that all persons signing on behalf of Landlord were authorized to do so by appropriate
actions. 
 Tenant hereby represents and warrants that neither Tenant, nor any persons or entities holding any legal or beneficial interest
whatsoever in Tenant, are (i) the target of any sanctions program that is established by Executive Order of the President or published by the Office of Foreign Assets Control, U.S. Department of the Treasury (“OFAC”);
(ii) designated by the President or OFAC pursuant to the Trading with the Enemy Act, 50 U.S.C. App. § 5, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-06, the Patriot Act, Public Law 107-56, Executive Order
13224 (September 23, 2001) or any Executive Order of the President issued pursuant to such statutes; or (iii) named on the following list that is published by OFAC: “List of Specially Designated Nationals and Blocked Persons.” If the
foregoing representation is untrue at any time during the Term, an Event of Default will be deemed to have occurred, without the necessity of notice to Tenant. 
 10. Incorporation. Except as modified herein, all other terms and conditions of the Lease shall continue in full force and effect and Tenant hereby ratifies and confirms its obligations thereunder.
Tenant acknowledges that, as of the date of the Amendment, Tenant (i) is not in default under the terms of the Lease; (ii) has no defense, set off or counterclaim to the enforcement by Landlord of the terms of the Lease; and (iii) is
not aware of any action or inaction by Landlord that would constitute a default by Landlord under the Lease. 
 11.
Limitation of Landlord Liability. Redress for any claims against Landlord under the Lease and this Amendment shall only be made against Landlord to the extent of Landlord’s interest in the property to which the Premises are a part, the
rents, issues and proceeds thereof. The obligations of Landlord under the Lease and this Amendment shall not be personally binding on, nor shall any resort be had to the private properties of, any of its trustees or board of directors and officers,
as the case may be, the general partners thereof or any beneficiaries, stockholders, employees or agents of Landlord, or the investment manager, and in no case shall Landlord be liable to Tenant, or Tenant be liable to Landlord, hereunder for any
lost profits, damage to business, or any form of special, indirect or consequential damages. 

  
 3 

 IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the day and year
first written above. 
  

									
	LANDLORD:	 		 	TENANT:
			
	RREEF AMERICA REIT II CORP. PPP,
a Maryland corporation	 		 	AEGERION PHARMACEUTICALS, INC,
a Delaware corporation
					
	By:	 	/s/ Robert D. Seaman	 		 	By:	 	/s/ Marc D. Beer
	Name:	 	Robert D. Seaman	 		 	Name:	 	Marc D. Beer
	Title:	 	Vice President	 		 	Title:	 	CEO
					
	Dated:	 	November 15, 2011	 		 	Dated:	 	November 15, 2011

  
 4 

 EXHIBIT A—ADDITIONAL SPACE 

attached to and made a part of First Amendment to Lease 
 dated of November 7, 2011 between 
 RREEF AMERICA REIT II CORP. PPP,
as Landlord and 
 AEGERION PHARMACEUTICALS, INC. as Tenant 

101 Main Street, Cambridge, Massachusetts 02142 
  

 
  

					
		  	 	  	RDS
		  	Initials

 EXHIBIT B—SECOND ADDITIONAL SPACE 

attached to and made a part of First Amendment to Lease 
 dated of November 7, 2011 between 
 RREEF AMERICA REIT II CORP. PPP,
as Landlord and 
 AEGERION PHARMACEUTICALS, INC. as Tenant 

101 Main Street, Cambridge, Massachusetts 02142 
  

 
  

					
		  	 	  	RDS
		  	Initials

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]